The Silent Crisis: Why Cutting Autopsy Services for a Fatal Brain Disease is a Dangerous Gamble
There’s a quiet crisis brewing in Canada’s healthcare system, and it’s one that most people haven’t even heard about. It revolves around Creutzfeldt-Jakob disease (CJD), a rare but fatal brain illness linked to mad cow disease. What’s alarming isn’t just the disease itself—it’s the federal government’s decision to cut funding for autopsy services that help diagnose it. Personally, I think this move is a textbook example of short-term cost-cutting with potentially devastating long-term consequences.
The Decision That Sparked Outrage
In February, the Public Health Agency of Canada (PHAC) abruptly halted funding for CJD autopsies and biopsies performed at the University of Ottawa lab. This lab had been the cornerstone of CJD diagnosis for decades, handling brain and tissue samples from across the country. The rationale? PHAC claims modern lab tests can now detect CJD in living patients, making autopsies less necessary. But here’s where things get interesting: neuropathologists—the experts who study diseases like CJD—are sounding the alarm. They argue that these tests aren’t foolproof, and autopsies remain crucial for accurate diagnosis, especially in inherited cases.
What makes this particularly fascinating is the disconnect between the government’s logic and the reality on the ground. PHAC’s decision seems to prioritize cost savings over scientific rigor. The program’s annual budget was reportedly up to $1.3 million, but as Dr. Gerard Jansen, who ran the program, pointed out, the actual federal contribution was significantly less because the number of autopsies performed was often half the budgeted amount. If you take a step back and think about it, this isn’t just about money—it’s about the value we place on diagnostic accuracy and public health preparedness.
The Hidden Risks of a Decentralized Approach
The Canadian Association of Neuropathologists has called PHAC’s move “short-sighted,” and I couldn’t agree more. Their letter to health officials highlights a critical point: decentralizing CJD diagnosis would be far more expensive and time-consuming. Building the necessary expertise and infrastructure across provinces would take years, leaving a diagnostic gap that could have serious consequences. What many people don’t realize is that CJD isn’t just a medical mystery—it’s a public health threat. Misdiagnosis or delayed diagnosis could lead to the spread of this transmissible disease, especially in cases linked to mad cow disease.
One thing that immediately stands out is the lack of consultation with neuropathologists before the decision was made. Dr. Cynthia Hawkins, president of the neuropathology association, noted that PHAC didn’t even discuss alternatives with the experts who’ve been on the front lines of CJD surveillance for 30 years. This raises a deeper question: How can we trust public health decisions when they’re made without input from the very people who understand the issue best?
The Human Cost of a Policy Decision
CJD is rare, with fewer than 500 cases confirmed in Canada since 2020. But rarity doesn’t diminish the disease’s impact. It’s incurable, progresses rapidly, and often goes undetected until it’s too late. The neuropathologists’ letter cites a recent case where an inherited form of CJD was only identified at autopsy after lab tests had ruled it out. This isn’t just a statistical anomaly—it’s a stark reminder of the limitations of current diagnostic tools.
From my perspective, this isn’t just about saving money; it’s about prioritizing human lives. Cutting autopsy services could lead to missed diagnoses, delayed research, and a false sense of security about CJD’s prevalence. What this really suggests is that we’re willing to gamble with public health for the sake of short-term savings.
A Broader Trend in Public Health
This decision doesn’t exist in a vacuum. It’s part of a broader trend of underfunding and neglecting critical public health infrastructure. In a world where emerging diseases like COVID-19 have shown us the importance of preparedness, cutting diagnostic services for a fatal brain disease feels like a step backward. If we’ve learned anything from recent pandemics, it’s that investing in surveillance and diagnostics isn’t just a luxury—it’s a necessity.
Where Do We Go From Here?
PHAC is reportedly preparing a response to the neuropathologists’ letter, but the damage may already be done. The program has been halted, and the expertise built over decades is at risk of being lost. In my opinion, the government needs to reverse this decision and engage in a meaningful dialogue with experts to find a sustainable solution.
What’s at stake here isn’t just a budget line—it’s our ability to diagnose, understand, and ultimately combat a deadly disease. If we fail to act, we’re not just cutting costs; we’re cutting corners on public health. And that’s a gamble we can’t afford to take.
